INCY Stock: Incyte Corporation Stock Price, Analysis & Insights
Get live incy stock price $105.98, comprehensive Incyte Corporation stock analysis, charts, news, and expert forecast. Real-time incy stock data and investment insights.
Loading chart...
Company Overview
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Company Information
- CEO
- Herve Hoppenot
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2617
Contact Information
- Website
- https://www.incyte.com
- Address
- 1801 Augustine Cut-Off
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 18.0)
Business Model & Strategy
Incyte Corporation operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Herve Hoppenot, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Incyte Corporation competes in the Biotechnology within the broader Healthcare. With 20.8 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Incyte Corporation provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Incyte Corporation should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Incyte Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Incyte Corporation
- ⚠Investors should consider how Incyte Corporation fits within their overall portfolio allocation
Market Cap
20.81B
P/E Ratio
17.96
Beta
0.83
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 20.81B market capitalization
- Trading Volume: 1.90M shares traded today
- Price Range: 52-week range of $53.56 - $106.47
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Incyte Corporation
Incyte Corporation (INCY) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 20.81B, the company represents a significant player in its market. The stock is currently trading at $105.98 with a positivedaily change of 0.74%.
The company's 2617 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 17.96, beta of 0.83, and 52-week price range from $53.56 to $106.47when evaluating investment opportunities.
Why Invest in Incyte Corporation?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Herve Hoppenot
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.